微生物与生化药学——药理学方向

何红伟

来源:    

作者:    

时间:2021-07-01    

浏览次数:


何红伟   肿瘤室副主任   研究员   博士生导师

教育背景及工作经历:

1999年本科、2002年硕士毕业于首都师范大学,2005年博士毕业于协和医科大学(现北京协和医学院),之后就职于中国医学科学院&北京协和医学院医药生物技术研究所,2006年赴新泽西公共健康研究所(PHRI)访问,2008年赴耶鲁大学进修博士后。

主要研究方向:肿瘤分子药理和肝脏疾病分子药理

专业研究领域:主要研究肝炎、肝纤维化与肝硬化、肝癌及三者之间的演化过程,注重动物模型和分子机理的结合,探索疾病发生、发展过程中的新机制,寻找新药物作用靶点,阐述已有药物的新机理,研发新的具有自主知识产权的靶向药物。

代表性论文:

1.Zhang N, Zhao SS, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel biphenyl compound IMB-S7 ameliorates hepatic fibrosis in BDL rats by suppressing Sp1-mediated integrin αv expression. Acta Pharmacol Sin. 2020 May;41(5): 661- 669.

2.Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao YY, Huang R, Yu DK*, Shao RG*, He HW*. Costunolide represses hepatic fibrosis through WWP2-mediated Notch3 degradation. Br J Pharmacol. 2020 Jan;177(2):372-387.

3.Ge MX, Niu WX, Ren JF, Cai SY, Yu DK, Liu HT, Zhang N, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.Acta Pharmacologica Sinica. 2019 Jul;40(7):895-907.

4.Zhao SS, Li NR, Zhao WL, Liu H, Ge MX, Zhang YX, Zhao LY, You XF, He HW*, Shao RG*. D-chiro-inositol attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress, Acta Pharmacologica Sinica. 2018 Feb, 39(2): 213-221.

5.Ge M, Liu H, Zhang Y, Li N, Zhao S, Zhao W, Zhen Y, Yu J, He H*, Shao RG*. The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br J Pharmacol. 2017 May; 174(10):1147-1160.

6.Zhao S, Li N, Zhen Y, Ge M, Li Y, Yu B, He H*, Shao RG*. Protective effect of gastrodin on bile duct ligation-induced hepatic fibrosis in rats. Food Chem Toxicol. 2015 Oct 21;86:202-207.

7.Dong-ke YU, Cai-xia ZHANG, Shuang-shuang ZHAO, Sheng-hua ZHANG, Hao ZHANG, Shi-Ying CAI, Rong-guang SHAO, Hong-wei HE*, The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway. Acta Pharmacologica Sinica (2015) 36: 473–482.

8.Hongwei He, Albert Mennone, James L. Boyer, and Shi-Ying Cai. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct ligated rats and human hepatic cells. Hepatology. 2011 ;53(2):548-57.

代表性专利:

1. USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS,美国发明专利号:10,933,038,授权日:202132日;

2. 2-苯磺酰胺基苯甲酰胺类化合物在制备治疗肝癌药物中的应用,中国发明专利号:ZL202010139558.3,授权公告日:202129日;

3. 12N-取代胺甲酰基苦参碱衍生物及其制备方法和用途。申请号:2019101444411。授权公告日:202051日;

4. D手性肌醇在制备抗肝纤维化药物中的应用,中国发明专利申请号:ZL201610112806.9。申请日期:2016.03.01。 授权公告日:2019122日;

5. 2-苯磺酰胺基苯甲酰胺类化合物在肝损伤保护和肝纤维化防治中的应用,中国发明专利号:ZL201510830392.9。 授权公告日:20171114日;

6. 天麻素/天麻粉在制备抗肝纤维化药物中的应用,专利号: ZL201510019139.5, 授权公告日:2017818日;

7. 新型钠离子牛黄胆酸共转运多肽抑制剂,专利号:2015102907198。授权公告日:2017517日。

专著:参编《基因工程药物》、《抗体药物研究与应用》等专著。

荣誉奖励:2017年中国药学会-赛诺菲青年生物药物奖

学术任职:中国抗癌协会抗癌药物专业委员会、中国药理学会肿瘤药理专业委员会委员

联系电话:13691213210

电子邮箱: hehwei@imb.pumc.edu.cn